Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting
Zimmer Biomet (NYSE: ZBH) showcased its diverse orthopedic and musculoskeletal innovations at the AAOS 2025 Annual Meeting in San Diego, March 10-14. The company highlighted its comprehensive hip portfolio, featuring the new Z1™ Triple-Taper Femoral Hip System, alongside latest knee and upper extremity reconstruction technologies.
Key highlights include the newly cleared Persona® Revision SoluTion™ Femur for metal-sensitive patients, and the debut of ZBX™, their new Ambulatory Surgery Center solution. The showcase also featured innovative technologies like the HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, HipInsight™ System for mixed reality navigation, and the OsseoFit™ Stemless Shoulder System.
CEO Ivan Tornos emphasized that the company is experiencing one of its largest innovation cycles, positioning Zimmer Biomet at the forefront of customer-centric innovations focused on improving efficiency and patient outcomes.
Zimmer Biomet (NYSE: ZBH) ha presentato le sue diverse innovazioni ortopediche e muscoloscheletriche all'AAOS 2025 Annual Meeting a San Diego, dal 10 al 14 marzo. L'azienda ha messo in evidenza il suo portafoglio completo per l'anca, con il nuovo Z1™ Triple-Taper Femoral Hip System, insieme alle più recenti tecnologie per la ricostruzione del ginocchio e degli arti superiori.
I punti salienti includono il nuovo Persona® Revision SoluTion™ Femur per pazienti sensibili ai metalli e il debutto del ZBX™, la loro nuova soluzione per i Centri di Chirurgia Ambulatoriale. La presentazione ha anche mostrato tecnologie innovative come il HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, il HipInsight™ System per la navigazione in realtà mista e il OsseoFit™ Stemless Shoulder System.
Il CEO Ivan Tornos ha sottolineato che l'azienda sta vivendo uno dei suoi più grandi cicli di innovazione, posizionando Zimmer Biomet all'avanguardia delle innovazioni centrate sul cliente, focalizzate sul miglioramento dell'efficienza e dei risultati per i pazienti.
Zimmer Biomet (NYSE: ZBH) mostró sus diversas innovaciones ortopédicas y musculoesqueléticas en la AAOS 2025 Annual Meeting en San Diego, del 10 al 14 de marzo. La empresa destacó su completo portafolio de caderas, presentando el nuevo Z1™ Triple-Taper Femoral Hip System, junto con las últimas tecnologías de reconstrucción de rodilla y extremidades superiores.
Los puntos clave incluyen el recién aprobado Persona® Revision SoluTion™ Femur para pacientes sensibles a metales, y el debut del ZBX™, su nueva solución para Centros de Cirugía Ambulatoria. La exhibición también presentó tecnologías innovadoras como el HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, el HipInsight™ System para navegación en realidad mixta y el OsseoFit™ Stemless Shoulder System.
El CEO Ivan Tornos enfatizó que la empresa está experimentando uno de sus mayores ciclos de innovación, posicionando a Zimmer Biomet a la vanguardia de las innovaciones centradas en el cliente, enfocadas en mejorar la eficiencia y los resultados para los pacientes.
짐머 바이오메트 (NYSE: ZBH)는 3월 10일부터 14일까지 샌디에이고에서 열린 AAOS 2025 연례 회의에서 다양한 정형외과 및 근골격계 혁신을 선보였습니다. 이 회사는 새로운 Z1™ Triple-Taper Femoral Hip System을 포함한 포괄적인 고관절 포트폴리오와 최신 무릎 및 상지 재건 기술을 강조했습니다.
주요 하이라이트로는 금속에 민감한 환자를 위한 새롭게 승인된 Persona® Revision SoluTion™ Femur와 그들의 새로운 외래 수술 센터 솔루션인 ZBX™의 데뷔가 있습니다. 전시회에서는 HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, 혼합 현실 내비게이션을 위한 HipInsight™ System, OsseoFit™ Stemless Shoulder System과 같은 혁신적인 기술도 소개되었습니다.
CEO 이반 토르노스는 회사가 고객 중심 혁신의 최전선에 서게 하는 가장 큰 혁신 주기를 경험하고 있다고 강조했습니다. 이는 효율성과 환자 결과를 개선하는 데 중점을 두고 있습니다.
Zimmer Biomet (NYSE: ZBH) a présenté ses diverses innovations orthopédiques et musculo-squelettiques lors de la AAOS 2025 Annual Meeting à San Diego, du 10 au 14 mars. L'entreprise a mis en avant son portefeuille complet de hanches, avec le nouveau Z1™ Triple-Taper Femoral Hip System, ainsi que les dernières technologies de reconstruction du genou et des membres supérieurs.
Les points forts incluent le nouveau Persona® Revision SoluTion™ Femur pour les patients sensibles aux métaux, et le lancement du ZBX™, leur nouvelle solution pour les centres de chirurgie ambulatoire. L'exposition a également présenté des technologies innovantes telles que le HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, le HipInsight™ System pour la navigation en réalité mixte et le OsseoFit™ Stemless Shoulder System.
Le PDG Ivan Tornos a souligné que l'entreprise connaît l'un de ses plus grands cycles d'innovation, plaçant Zimmer Biomet à l'avant-garde des innovations centrées sur le client, axées sur l'amélioration de l'efficacité et des résultats pour les patients.
Zimmer Biomet (NYSE: ZBH) stellte seine vielfältigen orthopädischen und muskuloskelettalen Innovationen auf dem AAOS 2025 Annual Meeting in San Diego vom 10. bis 14. März vor. Das Unternehmen hob sein umfassendes Hüftportfolio hervor, das das neue Z1™ Triple-Taper Femoral Hip System sowie die neuesten Technologien zur Rekonstruktion des Knies und der oberen Extremitäten umfasst.
Zu den wichtigsten Highlights gehören die neu zugelassene Persona® Revision SoluTion™ Femur für metallempfindliche Patienten und die Premiere des ZBX™, ihrer neuen Lösung für ambulante chirurgische Zentren. Die Ausstellung zeigte auch innovative Technologien wie das HAMMR® Automated Hip Impaction System, OrthoGrid Hip AI®, das HipInsight™ System für Mixed-Reality-Navigation und das OsseoFit™ Stemless Shoulder System.
CEO Ivan Tornos betonte, dass das Unternehmen einen seiner größten Innovationszyklen erlebt, wodurch Zimmer Biomet an der Spitze der kundenorientierten Innovationen steht, die darauf abzielen, die Effizienz und die Ergebnisse für die Patienten zu verbessern.
- Major innovation cycle with multiple new product launches across hip, knee, and shoulder segments
- Introduction of ZBX™ ASC solutions expanding market reach into ambulatory surgery centers
- Launch of Persona® Revision SoluTion™ Femur addressing unmet need for metal-sensitive patients
- Integration of advanced technologies (AI, mixed reality) in surgical solutions
- None.
Insights
Zimmer Biomet's showcase at AAOS 2025 represents a strategically timed portfolio expansion across multiple orthopedic segments. The announcement of the recently cleared Persona® Revision SoluTion™ Femur and debut of ZBX™ Ambulatory Surgery Center Solutions are particularly notable developments that address specific market needs.
The company's emphasis on its comprehensive hip portfolio anchored by the new Z1™ Triple-Taper Femoral Hip System, alongside technologies specifically designed for metal-sensitive patients, demonstrates a targeted approach to clinical differentiation. CEO Ivan Tornos's characterization of this as "one of the largest innovation cycles" in company history signals the strategic importance of these product launches.
The ZBX™ program targeting Ambulatory Surgery Centers is especially significant as it positions Zimmer Biomet to capitalize on the shift toward outpatient orthopedic procedures. This strategic move acknowledges the changing care delivery landscape where ASCs are becoming increasingly important settings for orthopedic surgeries.
The diverse portfolio being highlighted—spanning hip reconstruction with AI and mixed reality capabilities, metal-sensitivity conscious knee options, and stemless shoulder systems—indicates a balanced approach to innovation across all major joint replacement categories. While these appear to be evolutionary rather than revolutionary advancements, they collectively strengthen Zimmer Biomet's competitive positioning in the orthopedic market.
Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions
WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in
"I am thrilled to showcase the collective strength and broad range of our musculoskeletal portfolio, including the introduction of several recently cleared technologies, at this year's annual AAOS meeting," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with our comprehensive knee portfolio with constructs designed to safeguard against cement and metal sensitivities, our bone-preserving stemless shoulder and now an enhanced suite of ASC solutions, squarely position us at the forefront of delivering customer-centric innovations to improve efficiency and overall patient outcomes."
The highlights at the Zimmer Biomet booth (#3129) include:
Hip Reconstruction Technologies
- Z1™ Femoral Hip System, a triple-taper design with expansive innovations within a more comprehensive system, providing more solutions to treat more patients.
- HAMMR® Automated Hip Impaction System, designed to address surgeon strain, fatigue and repetitive motion associated with traditional mallet use during bone preparation and device implantation.
- OrthoGrid Hip AI®, an AI-powered, fluoroscopy-based technology that provides direct anterior (DA) hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.1
- HipInsight™ System, the first FDA-cleared mixed reality system for hip navigation offers intuitive, intra-operative guidance that leverages the Microsoft HoloLens 2 (mixed reality headset) to help visualize and guide accurate2 acetabular component placement and alignment in real-time.
Knee Reconstruction Technologies
- Persona® Revision SoluTion™ Femur, a newly cleared revision knee implant component, part of the comprehensive Persona Revision Knee System, offering an alternative to cobalt-chrome (Co-Cr-Mo) alloy for patients with sensitivities to certain metals.
- Oxford® Cementless Partial Knee, the only FDA-approved cementless partial knee implant in the
U.S. that has been shown to be efficient3,4 in the OR, and has been proven to have excellent longevity5,6 worldwide. - Persona® OsseoTi® Keel Tibia, a cementless anatomic tibia with a 3D printed porous tray from our clinically proven Persona Knee System5-7 designed to deliver stable initial and biological fixation and intra-operative versatility.8
- Persona IQ® 30 mm Stem, the world's only smart knee implant, now in a 30 mm stem length, that collects data directly from the knee to provide post-operative recovery insights9,10 and trends, allowing care teams to monitor and personalize the total knee arthroplasty patient experience9-11 with the goal of improving practice efficiency.12-15
Upper Extremities Technology
- OsseoFit™ Stemless Shoulder System, an anatomically shaped,16-18 asymmetric stemless shoulder implant designed for stable initial19-22 and biological fixation23, 24 by optimizing anatomic humeral fit for stemless shoulder arthroplasty.
ASC Solutions
- ZBX, Zimmer Biomet's new comprehensive ASC program offering surgeons an experienced partner to strategically incorporate solutions, unique to each surgeon's needs, providing efficiency in the OR and beyond.
For more information about Zimmer Biomet events at AAOS 2025, visit www.zimmerbiomet.com/academy2025.
Important Safety Information for Oxford Cementless Partial Knee:
The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
References:
- Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.
- Dilbone ES, Heimann AF, Leal J, Ryan SP, Wellman SS. Evaluating the Accuracy of a Computed Tomography-Based Mixed-Reality Navigation Tool for Acetabular Component Positioning in Total Hip Arthroplasty. The Journal of Arthroplasty. 2025.
- Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.
- Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307
- NJR-
UK . The National Joint Registry 21st Annual Report 2024 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%202024_Knees.pdf. - AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.
- American Joint Replacement Registry (AJRR): 2024 Annual Report.
Rosemont, IL : American Academy of Orthopaedic Surgeons (AAOS), 2024. https://www.aaos.org/registries/publications/ajrr-annual-report/#:~:text=When%20citing%20any%20Annual%20Report,at%20RegistryEngagement%40aaos.org
National Joint Registry ofEngland ,Wales ,Northern Ireland , theIsle of Man andGuernsey . 20th Annual Report 2023 - Mueller JK, et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022
- Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039
- Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022
- Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A TOTAL KNEE ARTHROPLASTY PROSTHESIS CAPABLE OF REMOTE PATIENT MONITORING. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018
- Yocum DS, Redfern RE, Yergler JD. Delayed Recovery Following Total Knee Arthroplasty Identified by Remote Monitoring With Tibial Extension Sensors. Arthroplasty Today. 2023/10/01/ 2023;23:101188. doi: https://doi.org/10.1016/j.artd.2023.101188
- Yocum D, HousholderE, Yergler J. Manipulation under Anesthesia Following TKA with Persona IQ: A Case Series. J OrthopCase Rep. Aug 2023;13(8):127-131. doi:10.13107/jocr.2023.v13.i08.3844
- Dundon J, Aubin P, Hunter W. Objective Gait Analysis Following Total Knee Arthroplasty with a Smart Implant Directs Early Intervention with Manipulation under Anesthesia. Journal of OrthopaedicExperience & Innovation. 2024;Februarydoi:https://doi.org/10.60118/001c.89961.
- Parikh N, Redfern R, Yocum D, Andel D V, Yergler J. MT46 Patient Experience and Outcomes with Post-Surgical Remote Monitoring for Patients with Total Knee Arthroplasty (TKA). Value in Health. 2024/06/01/ 2024;27(6, Supplement):S290. doi:https://doi.org/10.1016/j.jval.2024.03
- Mueri, C, Snethen, K, Parisi, R, Son, Yang, Duquin, T Characterization of the Asymmetric Bone Envelope of the Proximal Humeral Metaphysis for Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1175; 2025 Feb 7-11;
Phoenix, Arizona . - Son, Y, Mueri, C, Snethen, K, Bowman, L, Parisi, R, Duquin, T Optimizing Stemless Humeral Anchors: Asymmetrical Designs for Minimizing Cortical Bone Impingement while Maximizing Cancellous Bone Purchase. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 2051; 2025 Feb 7-11;
Phoenix, Arizona . - ZRR_WI_6743_24. Analysis of Potential Cortical Perforation for the OsseoFit Stemless Shoulder. Zimmer Biomet Internal Research Report on File.
- Snethen, K, Mueri, C, Kriska, T, Son, Y, Bandi, M The Sensitivity of the Stability of Stemless Humeral Implants to Surgical, Patient and Design Factors in Reverse Shoulder Arthroplasty. Presented at the ORS Orthopaedic Research Society Annual Meeting; 2023,
Dallas, Texas . - Snethen, K, Son, Y, Mueri, C, Bischoff, J The Effect of Press-fit on Initial Stability in Stemless Shoulder Arthroplasty. Presented at the ISTA International Society for Technology in Arthroplasty Annual Meeting; 2022,
Maui, Hawaii . - Snethen, K, Mueri, C, Son, Y, Parisi, R, Duquin, T The Effect of Geometric Design on Initial Stability of Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1168; 2025 Feb 7-11;
Phoenix, Arizona . - ZBTR_30118. Anchor-Level Micromotion of the OsseoFit Stemless Shoulder with Application in Anatomic Total Shoulder Arthroplasty. Zimmer Biomet Internal Design Verification Report on File.
- Gupta, G Evaluation of Bony Ingrowth Implant Materials in an In Vivo Sheep Long Bone Defect Model 12-04/12-07, February 2013. 32.
- Gupta, G OsseoTi Porous Metal For Enhanced Bone Integration: an Animal Study. White Paper. 2014. Form No. BMET0718.0-GBL • REV1214.
Laboratory and animal studies are not necessarily indicative of clinical performance.
HipInsight™ System is a trademark of Surgical Planning Associates, Inc.
Microsoft and HoloLens 2 are trademarks of the Microsoft Corporation.
Persona IQ: The objective kinematic data generated by the Canary Canturio® Tibial Extension with CHIRP® System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.
345 E. Main St.
www.zimmerbiomet.com
Media | Investors |
Heather Zoumas-Lubeski | David DeMartino |
445-248-0577 | 646-531-6115 |
Kirsten Fallon | Zach Weiner |
781-779-5561 | 908-591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-diverse-portfolio-of-orthopedic--musculoskeletal-innovations-at-aaos-2025-annual-meeting-302396091.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
What new products did Zimmer Biomet (ZBH) showcase at AAOS 2025?
What is the significance of Zimmer Biomet's new ZBX™ ASC offering?
How does the new Persona® Revision SoluTion™ Femur benefit patients?
What innovative hip technologies did ZBH present at AAOS 2025?
